Peptide
B7-33
SaveA single-chain relaxin peptide analog that selectively activates RXFP1 receptors, studied for anti-fibrotic and cardiovascular effects.
Quick verdict
Preclinical-stage analog designed to replicate relaxin-2 benefits with simpler manufacturing. No human trial data yet.
Evidence score
15/ 100
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Rodent studies show anti-fibrotic effects in cardiac and renal models. No human trials have been initiated.
Benefits
- Anti-fibrotic effects in preclinical cardiac models
- Simpler to synthesize than native relaxin-2
Dosage notes
No human dosing data available.
Side effects
- Unknown in humans
- Hypotension possible based on relaxin biology
Who should be cautious
Purely preclinical. No safety data in humans.
What this page cannot tell you
All data are from animal models. Translation to humans is uncertain.
Leaderboard scores
- Longevity15
- Recovery15
Write a review
Sign in to write a review.